www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Allergy immunotherapy
    • Healthcare professionals
      • Reweal
      • Webinars
    • Pipeline
    • Clinical trials
    • Clinical data sharing
  • Our company
    • Newsroom
      • Stories
    • Privacy
    • Global presence
    • Organisation
    • History
    • Owners
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Board of Management
      • Board of Directors
      • Annual general meeting
      • Annual general meeting (DK)
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
      • ADR Programme
    • Contact IR
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

Download library

DocumentType
Six-month interim report (Q2) 2023
Six-month interim report (Q2) 2023
Three-month interim report (Q1) 2023
FM_10_23UK_09052023.pdf
Annual General Meeting 2023 Minutes
Annual General Meeting 2023 Minutes
Referat generalforsamling 2023
Referat generalforsamling 2023
Annual report 2022
Annual report 2022
Corporate Governance 2022
Corporate Governance 2022
Statutory Corporate Governance Statement for 2022, cf. art. 107b of the Danish Financial Statements Act
Statutory Corporate Governance Statement for 2022, cf. art. 107b of the Danish Financial Statements Act
Annual Report 2022 (XHTML)
Annual Report 2022 (XHTML)
Key figures for 2022
Key figures for 2022
Nine-month interim report (Q3) 2022
Nine-month interim report (Q3) 2022

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
...
Next pagenext ›Last pagelast »
 
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved